Drug, device industries give mixed reactions on House health bill

The House health reform bill unveiled Thursday would require drug makers to pay an estimated $60 billion in Medicare reimbursements over the next 10 years and allow the federal government to negotiate prices directly with companies. The bill also would grant brand-name biotech-drug manufacturers 12 years exclusivity before generic rivals can be launched. The Advanced Medical Technology Association commended the legislation, which cuts proposed medical-device makers' tax to roughly $20 billion over the next decade.

View Full Article in:

Wall Street Journal (tiered subscription model), The · Hill, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT